Vmbook Online ordering

Medical Laboratories Research

Sure, here is some general information about Medical Laboratories Research (DGX)

Company Overview:

Medical Laboratories Research, also known as DGX, is a healthcare company in the United States. The company is a leading provider of pathology, toxicology, and clinical and anatomic services to physicians, hospitals, clinical trials, and pharmaceutical companies.

Financial Overview:

DGX is publicly traded on the New York Stock Exchange (NYSE) under the ticker symbol "DGX." Its Market capitalization is around $13.94 billion.

Earnings:

As of this writing, the company's most recent quarterly earnings report (Q2 2022) reported revenue of $260.1 million, up 16% year over year, beating estimates by $17.86 million. Net income was $29.7 million, and adjusted net income was $33.1 million. Adjusted EBITDA was $69.3 million, up 13% year over year. The company also revised its 2022 guidance, raising its revenue and adjusted EBITDA outlook.

Growth:

DGX has grown its revenue and income in recent years through strategic acquisitions, partnerships, and organic growth through increasing demand for its services. The company has also invested in digital technology to improve efficiency and customer experience. However, the company's growth may be affected by factors such as reimbursement rates, competition, and general economic conditions.

N Share:

DGX has a strong history of stock performance, with a 5-year annualized return of 17.81%. The company's shares have been up 2.36% over the past month, lagging behind the broader market by -18.81%. The stock closed at $173.79 on August 31, 2022, and its market capitalization was $13.94 billion. The stock's 52-week price range is $126.36-$228.14.

Investors' interest in DGX has been reflected in its stock performance, which has consistently outperformed the broader market. The company's strong fundamentals and positive outlook have made it an attractive choice for investors. However, investors should consider their investment goals and risk tolerance before investing in any stock, including DGX.

Please note that the information and figures mentioned regarding DGX's financial performance are subject to change and may not reflect the company's most current information.